Acura Pharmaceuticals, Inc.
ACUR
$0.001
-$0.0038-79.17%
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 2.25M | 2.39M | 3.12M | 3.57M | 4.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.25M | 2.39M | 3.12M | 3.57M | 4.07M |
| Cost of Revenue | 1.61M | 1.74M | 1.80M | 1.78M | 1.82M |
| Gross Profit | 635.00K | 641.00K | 1.32M | 1.79M | 2.26M |
| SG&A Expenses | 1.74M | 1.78M | 1.75M | 1.88M | 1.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35M | 3.53M | 3.54M | 3.66M | 3.76M |
| Operating Income | -1.11M | -1.14M | -421.00K | -90.00K | 310.00K |
| Income Before Tax | -1.15M | -1.57M | -872.00K | -1.21M | -810.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.15 | -1.57 | -0.87 | -1.21 | -0.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.15M | -1.57M | -872.00K | -1.21M | -810.00K |
| EBIT | -1.11M | -1.14M | -421.00K | -90.00K | 310.00K |
| EBITDA | -1.03M | -1.07M | -344.00K | 35.00K | 483.00K |
| EPS Basic | -0.03 | -0.05 | -0.03 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.02 | -0.01 | 0.00 |
| EPS Diluted | -0.03 | -0.05 | -0.03 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.02 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 183.28M | 140.06M | 129.47M | 129.28M | 128.67M |
| Average Diluted Shares Outstanding | 183.28M | 140.06M | 129.65M | 129.46M | 128.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
